LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 216 patients (estimated)
- Sponsors
- Incyte Corporation
- Tags
- Bromodomain and Extra-Terminal Protein (BET) Inhibitor, JAK1 Inhibitor, JAK2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1686
- NCT Identifier
- NCT04279847
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.